Improved survival with MEK inhibition in BRAF-mutated melanoma.

BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared t...

Full description

Bibliographic Details
Main Authors:	Flaherty, K, Robert, C, Hersey, P, Nathan, P, Garbe, C, Milhem, M, Demidov, L, Hassel, J, Rutkowski, P, Mohr, P, Dummer, R, Trefzer, U, Larkin, J, Utikal, J, Dreno, B, Nyakas, M, Middleton, M, Becker, J, Casey, M, Sherman, L, Wu, F, Ouellet, D, Martin, A, Patel, K, Schadendorf, D
Format:	Journal article
Language:	English
Published:	2012

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Similar Items